StreetInsider.com News Articles

Form 4 Korro Bio, Inc. For: Aug 26 Filed by: FORMELA JEAN FRANCOIS

Fri, 28 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260828/26998488.html

Form 4 Korro Bio, Inc. For: Aug 26 Filed by: FORMELA JEAN FRANCOIS

Fri, 28 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260828/26998488.html

Korro to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 07:00:00 -0400

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences:

Citi 2026 Biopharma Back to School Summit
Format: Fireside chat moderated by Yigal Nochomovitz, Ph.D., Director, Biotech Equity Research, Citi
Date: September 9^th, 2026
Time: 8:40 AM ET

2026 Cantor Global Healthcare Conference
Format: Fireside

Korro to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 07:00:00 -0400

Citi 2026 Biopharma Back to School Summit
Format: Fireside chat moderated by Yigal Nochomovitz, Ph.D., Director, Biotech Equity Research, Citi
Date: September 9^th, 2026
Time: 8:40 AM ET

2026 Cantor Global Healthcare Conference
Format: Fireside

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Wed, 26 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260826/26982944.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Wed, 26 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260826/26982944.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.

Wed, 26 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260826/26982948.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.

Wed, 26 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260826/26982948.html

Form 4 Korro Bio, Inc. For: Aug 19 Filed by: FORMELA JEAN FRANCOIS

Fri, 21 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260821/26961659.html

Form 4 Korro Bio, Inc. For: Aug 19 Filed by: FORMELA JEAN FRANCOIS

Fri, 21 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260821/26961659.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Wed, 19 Aug 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260819/26951297.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Wed, 19 Aug 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260819/26951297.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.

Wed, 19 Aug 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260819/26951298.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.

Wed, 19 Aug 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260819/26951298.html

Korro Bio files ethics submission for urea cycle disorder drug trial

Wed, 19 Aug 2026 16:08:27 -0400

Korro Bio (NASDAQ: KRRO) announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for its drug candidate KRRO-121, according to a company statement.

KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders (UCDs).

The Phase 1/2 trial is designed to evaluate the safety and tolerability of escalating doses, assess pharmacokinetics, and measure the drug's effect in both healthy volunteers and participants with UCDs. The announcement was made on August 19, 2026.

Additional trial information is available on ClinicalTrials.gov under identifier NCT

Korro Bio files ethics submission for urea cycle disorder drug trial

Wed, 19 Aug 2026 16:08:27 -0400

KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders (UCDs).

Additional trial information is available on ClinicalTrials.gov under identifier NCT

Form 8-K Korro Bio, Inc. For: Aug 19

Wed, 19 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260819/26950037.html

Form 8-K Korro Bio, Inc. For: Aug 19

Wed, 19 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260819/26950037.html

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 14 Aug 2026 16:05:00 -0400

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.

Korro granted the new employee a nonstatutory stock option to purchase 600 shares of Korro’s common stock at an exercise price of $13.35 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 14 Aug 2026 16:05:00 -0400

Form SCHEDULE 13G/A Korro Bio, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924113.html

Form SCHEDULE 13G/A Korro Bio, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924113.html

Form 4 Korro Bio, Inc. For: Aug 11 Filed by: FORMELA JEAN FRANCOIS

Thu, 13 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26922589.html

Form 4 Korro Bio, Inc. For: Aug 11 Filed by: FORMELA JEAN FRANCOIS

Thu, 13 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26922589.html

Form 4 Korro Bio, Inc. For: Aug 06 Filed by: Nichols Weston

Thu, 13 Aug 2026 09:54:00 -0400

si-local-file:///var/storage/secattach/20260813/26917893.html